Passive immunization with equine RBD-specific Fab protects K18-hACE2-mice against Alpha or Beta variants of SARS-CoV-2
Article
[키워드] ACE2 receptor binding
addition
administration
antibody
Beta
clearance
contributed
country
COVID-19
COVID-19 pandemic
creating
delta variant
disease
dose
doses
Efficacy
emergence
EpF(ab’)2
equine
Equine F(ab’)2
Fab
HBsAg
immunization
implementation
increased survival
Infection
intranasal
K18-hACE2
K18-hACE2 transgenic mice
mice
monoclonal antibody treatment
neutralize
omicron
outcome
pandemic
passive immunization
peripheral circulation
phenotype
polyclonal
polyclonal antibodies
PROTECT
RBD
SARS-CoV-2
SARS-COV-2 infection
Severe case
severe disease
severe SARS-CoV-2
strain
survival
tested
therapeutic
Therapeutic treatment
tissues
transgenic
Treatment
variant
variant of concern (VOC)
variants
variants of concern
variants of SARS-CoV-2
Viral RNA
virus
VoC
[DOI] 10.3389/fimmu.2022.948431 PMC 바로가기
[DOI] 10.3389/fimmu.2022.948431 PMC 바로가기